These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 24333111)

  • 1. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.
    Secanella-Fandos S; Noguera-Ortega E; Olivares F; Luquin M; Julián E
    J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Guérin substrains.
    Secanella-Fandos S; Luquin M; Julián E
    J Urol; 2013 Feb; 189(2):711-8. PubMed ID: 22982433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. γ Irradiated Mycobacteria Enhance Survival in Bladder Tumor Bearing Mice Although Less Efficaciously than Live Mycobacteria.
    Noguera-Ortega E; Rabanal RM; Secanella-Fandos S; Torrents E; Luquin M; Julián E
    J Urol; 2016 Jan; 195(1):198-205. PubMed ID: 26165584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of different Bacillus Calmette-Guerin substrains on growth inhibition of T24 bladder cancer cells and cytokines secretion by BCG activated peripheral blood mononuclear cells of PBMCs.
    Janaszek-Seydlitz W; Prygiel M; Bucholc B; Wiatrzyk A; Czajka U; Górska P; Soliwoda U
    Adv Clin Exp Med; 2014; 23(6):877-84. PubMed ID: 25618112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.
    Joraku A; Homhuan A; Kawai K; Yamamoto T; Miyazaki J; Kogure K; Yano I; Harashima H; Akaza H
    BJU Int; 2009 Mar; 103(5):686-93. PubMed ID: 19040525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury.
    Chen F; Zhang G; Cao Y; Payne R; See WA
    J Urol; 2007 Nov; 178(5):2166-70. PubMed ID: 17870116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR3 Down-Regulation is Involved in bacillus Calmette-Guérin Induced Bladder Tumor Growth Inhibition.
    Langle YV; Belgorosky D; Prack McCormick B; Sahores A; Góngora A; Baldi A; Lanari C; Lamb C; Eiján AM
    J Urol; 2016 Jan; 195(1):188-97. PubMed ID: 26144336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
    Chen F; Zhang G; Cao Y; Hessner MJ; See WA
    J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer.
    Reis LO; Ferreira U; Billis A; Cagnon VH; Fávaro WJ
    J Urol; 2012 Feb; 187(2):438-45. PubMed ID: 22177150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis.
    Boehm BE; Cornell JE; Wang H; Mukherjee N; Oppenheimer JS; Svatek RS
    J Urol; 2017 Sep; 198(3):503-510. PubMed ID: 28286068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human β-defensin 2 may inhibit internalisation of bacillus Calmette-Guérin (BCG) in bladder cancer cells.
    Kim JH; Kim SJ; Lee KM; Chang IH
    BJU Int; 2013 Oct; 112(6):781-90. PubMed ID: 23819923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of peroxisome proliferator activated receptor-gamma in bacillus Calmette-Guérin bladder cancer therapy.
    Langle Y; Lodillinsky C; Belgorosky D; Sandes EO; Eiján AM
    J Urol; 2012 Dec; 188(6):2384-90. PubMed ID: 23088980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
    Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y
    J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.
    Miyazaki J; Hinotsu S; Ishizuka N; Naito S; Ozono S; Akaza H; Nishiyama H
    Jpn J Clin Oncol; 2013 Aug; 43(8):827-34. PubMed ID: 23858038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Guerin for bladder urothelial cancer.
    Boorjian SA; Berglund RK; Maschino AC; Savage CJ; Herr HW
    J Urol; 2009 Oct; 182(4):1306-12. PubMed ID: 19683284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive biomarkers of response to bacillus Calmette-Guérin immunotherapy and bacillus Calmette-Guérin failure for non-muscle invasive bladder cancer.
    Wang Z; So WZ; Loh KY; Lim YK; Mahendran R; Wu QH; Chiong E
    Int J Urol; 2022 Aug; 29(8):807-815. PubMed ID: 35598896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
    Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Gonzalez M; Portillo J; Ojea A; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Montesinos M; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA
    J Urol; 2009 Nov; 182(5):2195-203. PubMed ID: 19758621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributors to HMGB1 release by urothelial carcinoma cells in response to bacillus Calmette-Guérin.
    Zhang G; Chen F; Cao Y; See WA
    J Urol; 2013 Oct; 190(4):1398-403. PubMed ID: 23583857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.